DTU Logo
Publications | Conference abstracts | Slidesets | Webcasts

Publications (9 of 405)


Search Publications :

2011

All That Glitters Is Not Gold: Why we need better trials and reporting
Rury R Holman
Diabetes Voice 2011;56:32. Published:Dec-2011. PMID:21767341. doi:10.1111/j.1463-1326.2011.01475.x

Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Farmer AJ, Oke J, Stevens R, Holman RR
Diabetes, Obesity and Metabolism 2011;13:1136-1141. Published:16-Nov-2011. doi:10.1111/j.1463-1326.2011.01475.x

Incidence of Diabetes Following Ramipril and Rosiglitazone Withdrawal
Rury R Holman FRCP, B Zinman, S Yusaf, P Sheridan, S Anand, J Bosch, I Conget, M Davies, V Pirags, J Pogue, P Zimmet, HC Gerstein.
Diabetes Care 2011;34:1265-1269 . Published:Jun-2011. Epub:22-Apr-2011. PMID:21515846. doi:10.2337/dc10-1567

Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
Julia Lawton, Nicholas Jenkins, Julie L Darbyshire, Rury R Holman, Andrew J Farmer and Nina Hallowell
Trials 2011;12: . Published:04-May-2011. PMID:21542916. doi:10.1186/1745-6215-12-108

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
John M. Lachin, Giancarlo Viberti, Bernard Zinman, Steven M. Haffner, R. Paul Aftring, Gitanjali Paul, Barbara G. Kravitz, William H. Herman, Rury R. Holman, Steven E. Kahn, ADOPT
Clin J Am Soc Nephrol 2011;6:1032-40. Published:May-2011. Epub:31-Mar-2011. PMID:21454723. doi:10.2215/CJN.09291010

Effects Of Rosiglitazone, Glyburide, and Metformin on beta-Cell Function and Insulin Sensitivity in ADOPT
Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; and the ADOPT Study Group
Diabetes 2011;60:1552-1560. Published:May-2011. Epub:17-Mar-2011. PMID:21415383. doi:10.2337/db10-1392

Patients' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study
N. Jenkins, N. Hallowell, A. J. Farmer, R. R. Holman, J. Lawton
Diabetic Medicine 2011;28:543-548. Published:May-2011. PMID:21480965. doi:10.1111/j.1464-5491.2010.03200.x

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals
The ARB Trialists Collaboration
Journal of Hypertension 2011;29:623-635. Published:Apr-2011. Epub:10-Feb-2011. PMID:21358417. doi:10.1097/HJH.0b013e328344a7de
Errata in :
Journal of Hypertension 2015;32:288, Print:Feb-2015, Epub:20-Jan-2015, doi:10.1111/dme.12672
Journal of Hypertension 2011;28:625, Print:May-2011, Epub:12-Apr-2011, doi:10.1111/j.1464-5491.2011.03267.x

Impact of personalised cardiovascular disease risk estimates on physical activity-a randomised controlled trial
Hermione C Price, Simon J Griffin, Rury R Holman
Diabetic Medicine 2011;28:363-372. Published:Mar-2011. Epub:10-Feb-2011. PMID:21309847. doi:10.1111/j.1464-5491.2010.03212.x
Erratum in :
Diabetic Medicine 2015;32:288, PMID:Feb-2015